Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aliskiren: Phase III data

Data from 458 evaluable patients in the double-blind, international Phase III AQUARIUS trial showed that once-daily 300 mg aliskiren given for >=72 weeks missed the primary endpoint of reducing the progression of coronary atherosclerosis, defined by

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers